CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-… Read more
CalciMedica, Inc. Common Stock (CALC) - Net Assets
Latest net assets as of December 2025: $-6.64 Million USD
Based on the latest financial reports, CalciMedica, Inc. Common Stock (CALC) has net assets worth $-6.64 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.59 Million) and total liabilities ($20.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.64 Million |
| % of Total Assets | -48.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | -110.21% |
| 10-Year Change | N/A |
| Growth Volatility | 135.66 |
CalciMedica, Inc. Common Stock - Net Assets Trend (2018–2025)
This chart illustrates how CalciMedica, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CalciMedica, Inc. Common Stock (2018–2025)
The table below shows the annual net assets of CalciMedica, Inc. Common Stock from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-6.64 Million | -146.09% |
| 2024-12-31 | $14.41 Million | +76.66% |
| 2023-12-31 | $8.16 Million | +188.35% |
| 2022-12-31 | $-9.23 Million | -114.20% |
| 2021-12-31 | $65.02 Million | -31.40% |
| 2020-12-31 | $94.79 Million | +233.65% |
| 2019-12-31 | $28.41 Million | +136.37% |
| 2018-12-31 | $12.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CalciMedica, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12052700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | % |
| Other Components | $182.68 Million | % |
| Total Equity | $-6.64 Million | 100.00% |
CalciMedica, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of CalciMedica, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Trailbreaker Resources Ltd
OTCQB:APRAF
|
$7.51 Million |
|
Veris Ltd
AU:VRS
|
$7.51 Million |
|
Lewis & Clark Bancorp
PINK:LWCL
|
$7.51 Million |
|
Axolot Solutions Holding AB
ST:AXOLOT
|
$7.52 Million |
|
Maris Tech Ltd
NASDAQ:MTEK
|
$7.50 Million |
|
Waskita Beton Precast Tbk PT
JK:WSBP
|
$7.50 Million |
|
Eason & Co Public Company Limited
BK:EASON
|
$7.50 Million |
|
City Service SE
WAR:CTS
|
$7.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CalciMedica, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,410,000 to -6,641,000, a change of -21,051,000 (-146.1%).
- Net loss of 29,562,000 reduced equity.
- New share issuances of 5,523,000 increased equity.
- Other comprehensive income decreased equity by 4,000.
- Other factors increased equity by 2,992,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.56 Million | -445.14% |
| Share Issuances | $5.52 Million | +83.17% |
| Other Comprehensive Income | $-4.00K | -0.06% |
| Other Changes | $2.99 Million | +45.05% |
| Total Change | $- | -146.09% |
Book Value vs Market Value Analysis
This analysis compares CalciMedica, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $14.02 | $0.83 | x |
| 2019-12-31 | $27.50 | $0.83 | x |
| 2020-12-31 | $200.50 | $0.83 | x |
| 2021-12-31 | $42.94 | $0.83 | x |
| 2022-12-31 | $-6.02 | $0.83 | x |
| 2023-12-31 | $1.82 | $0.83 | x |
| 2024-12-31 | $1.28 | $0.83 | x |
| 2025-12-31 | $0.00 | $0.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CalciMedica, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-120.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -236.11% | 0.00% | 0.00x | 1.48x | $-29.58 Million |
| 2019 | -130.37% | 0.00% | 0.00x | 1.43x | $-39.88 Million |
| 2020 | -29.05% | 0.00% | 0.00x | 1.07x | $-37.01 Million |
| 2021 | -55.09% | 0.00% | 0.00x | 1.06x | $-42.32 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.90 Million |
| 2023 | -421.20% | 0.00% | 0.00x | 1.49x | $-35.17 Million |
| 2024 | -95.07% | 0.00% | 0.00x | 1.37x | $-15.14 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.90 Million |
Industry Comparison
This section compares CalciMedica, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CalciMedica, Inc. Common Stock (CALC) | $-6.64 Million | -236.11% | N/A | $7.50 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |